Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma
Clinical trial NCT03619239 · COMPLETED
Trial details
- NCT number
- NCT03619239
- Sponsor
- Genexine, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-20
- Primary completion
- 2020-09-25
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.